Revaprazan hydrochloride is primarily used as a potent and selective acid pump antagonist in the treatment of gastric acid-related disorders. It effectively inhibits the gastric H+/K+-ATPase enzyme, reducing acid secretion in the stomach. This makes it a valuable therapeutic option for managing conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and gastritis. Its rapid onset of action and prolonged efficacy provide significant relief from symptoms like heartburn and acid regurgitation. Additionally, it is often preferred for patients who may not respond adequately to proton pump inhibitors (PPIs) or require an alternative treatment option. Its role in promoting mucosal healing and preventing ulcer recurrence further underscores its clinical importance.